This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clorox (CLX) Q3 Earnings Beat & Sales Miss, FY21 View Updated
by Zacks Equity Research
Clorox's (CLX) third-quarter fiscal 2021 earnings beat estimates but declined year over year on lower gross margins and increased advertising investments.
Factors to Watch Ahead of Sysco's (SYY) Q3 Earnings Release
by Zacks Equity Research
Sysco's (SYY) third-quarter fiscal 2021 results are likely to reflect softness in International unit owing to pandemic-led lockdown in various regions. Also, product cost inflation is a concern.
Here's How Medifast (MED) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
Strength in the OPTAVIA lifestyle solution and coaching support system have most likely aided Medifast's (MED) first-quarter 2021 performance.
Altria (MO) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) first-quarter performance is hurt by soft cigarette shipment volumes. Nevertheless, higher pricing continue to remain an upside.
What's in Store for The Estee Lauder Companies (EL) Q3 Earnings
by Zacks Equity Research
Strength in the Asia-Pacific region and solid online sales are likely to get reflected in The Estee Lauder Companies' (EL) third-quarter fiscal 2021 performance.
Factors to Watch Ahead of Church & Dwight (CHD) Q1 Earnings
by Zacks Equity Research
Church & Dwight's (CHD) first-quarter 2021 results are likely to reflect gains from the pandemic-led higher at-home consumption, though high marketing costs are likely to be a burden.
Factors to Watch Ahead of Hershey's (HSY) Q1 Earnings Release
by Zacks Equity Research
Hershey's (HSY) first-quarter 2021 results are likely to reflect strength in the North America segment and gains from innovation. However, softness in the International segment is a concern.
Factors to Watch Ahead of Pilgrim's Pride (PPC) Q1 Earnings
by Zacks Equity Research
Pilgrim's Pride's (PPC) first-quarter 2021 results are likely to benefit from a focus on key customers, though softness in the U.S. operations has been a concern.
Factors to Watch Ahead of Kraft Heinz's (KHC) Q1 Earnings
by Zacks Equity Research
Kraft Heinz's (KHC) first-quarter 2021 results are likely to reflect gains from the pandemic-led higher at-home consumption and efficient pricing, though high SG&A costs are concerning.
Helen of Troy (HELE) Queued for Q4 Earnings: Factors to Note
by Zacks Equity Research
Helen of Troy's (HELE) fourth-quarter fiscal 2021 results are likely to reflect gains from Leadership Brands and higher online sales.
Mondelez (MDLZ) Lined Up for Q1 Earnings: Key Things to Note
by Zacks Equity Research
Mondelez's (MDLZ) first-quarter 2021 results are likely to reflect gains from acquisitions and saving efforts amid weakness in some emerging markets and high COVID-19 costs.
Archer Daniels (ADM) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Archer Daniels' (ADM) Q1 revenues are likely to have benefited from momentum in its Nutrition segment, driven by strength in Animal and Human Nutrition businesses.
Philip Morris (PM) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Philip Morris' (PM) first-quarter performance reflects gains from favorable pricing variance as well as growth in heated tobacco shipment volumes.
The Estee Lauder Companies (EL) Looks Radiant: Here's Why
by Zacks Equity Research
The Estee Lauder Companies (EL) Skin Care portfolio is performing well. Also, the company is on track with cost-saving measures.
Factors Likely to Influence Boston Beer's (SAM) Q1 Earnings
by Zacks Equity Research
Boston Beer (SAM) is expected to have benefited from strong depletion and shipment growth as well as innovation in Q1. Also, strength in brands and its cost-saving initiatives bode well.
Kimberly-Clark (KMB) Queued for Q1 Earnings: Factors to Note
by Zacks Equity Research
Kimberly-Clark's (KMB) first-quarter 2021 results are likely to reflect escalated costs and softness in the K-C Professional unit, though the Consumer Tissue segment should offer some respite.
Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.
Medifast (MED) Rallies More Than 25% in 6 Months: Here's Why
by Zacks Equity Research
Medifast (MED) has been benefiting from its OPTAVIA lifestyle solution and coaching support system, which is well placed given consumers' rising inclination toward health and wellness.
Why Is Medifast (MED) Down 11.9% Since Last Earnings Report?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lamb Weston's (LW) China Investment to Fuel Production Capacity
by Zacks Equity Research
Lamb Weston (LW) unveils plans to build a new french fry processing facility in Ulanqab, Inner Mongolia, China. Additionally, the company declares a quarterly dividend.
Nu Skin (NUS) More Than Doubles in a Year: Innovation a Driver
by Zacks Equity Research
Nu Skin (NUS) is optimistic about momentum in 2021, driven by impressive product pipeline, robust digital efforts along with steady improvement in customers and sales leaders.
The J.M. Smucker's (SJM) Deal With JDE Peet's to Aid Growth
by Zacks Equity Research
The J. M. Smucker (SJM) teams up with JDE Peet's, which is likely to support the former's Away From Home liquid coffee business.
General Mills (GIS) Q3 Earnings Lag Estimates, Sales Grow Y/Y
by Zacks Equity Research
General Mills' (GIS) third-quarter fiscal 2021 results reflect increased at-home demand amid the pandemic. However, high input costs are a concern.
General Mills (GIS) Strikes Deal With Sodiaal to Drive Growth
by Zacks Equity Research
General Mills (GIS) to offload 51% controlling interest in Yoplait S.A.S. to Sodiaal, in exchange of complete ownership of the Canadian Yoplait business.
Medifast (MED) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.